Peer-influenced content. Sources you trust. No registration required. This is HCN.
Modern Optometry
New pharmaceutical interventions are significantly broadening the scope of presbyopia treatment. Discover how these emerging options can enhance your practice and improve patient care.
Optometry September 26th 2023
Cancer Therapy Advisor
Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.
Oncology, Medical September 25th 2023
The New England Journal of Medicine
The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.
MDLinx
Discover how MatchMiner is transforming the landscape of precision medicine by efficiently connecting patients with suitable clinical trials, thereby accelerating the adoption of personalized therapies.
Oncology, Medical September 19th 2023
Roswell Park
Discover how Roswell Park’s phase 2 clinical trials are exploring the potential of propranolol to enhance the efficacy of immunotherapies in treating esophageal cancer. This could represent a significant shift in treatment protocols.
OBR Oncology
New data from the FLAURA2 trial suggests a promising but complex treatment landscape for EGFR-mutated advanced NSCLC. Physicians should weigh the significant PFS benefits against the increased risk of adverse events before considering this combination as a first-line treatment option.